Get Ready for DECEMBER (110%) approval
Vivus going to be the same as OREX.
Contrave launched in the beginning of October and has seen soft numbers ... the firsttwo weeks would total about 6,000 scripts, a launch that is on track ... The possibility of 5,000 unaccounted for scripts in the first two weeks is...11000
Today Orexigen (NASDAQ:OREX) offered a bit of a bombshell to the sector when it reported its quarterly earnings. The bombshell was not the fact that milestones payments brought a profit. The bombshell came in the form of how many scripts for Contrave have been written in just two weeks. Orexigen launched Contrave on October 20th, and by November 5th the tally on scripts written and submitted to the "Direct Save" program were at 5,000. Set aside whether all of these fill or not for a moment. Orexigen getting 5,000 scripts written and submitted to the Direct Save program is impressive.
Introducing CONTRAVE—a new, FDA-approved treatment for weight loss in obese adults
CONTRAVE is a prescription medicine that contains 2 medicines (naltrexone HCl and bupropion HCl) that may help some obese adults*, or overweight adults who also have weight-related medical problems†, lose weight and keep the weight off.
CONTRAVE should be used with a reduced calorie diet and increased physical activity.
It is not known if CONTRAVE changes your risk of heart problems or stroke or of death due to heart problems or stroke.
It is not known if CONTRAVE is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products.
1) Contrave (NB32) is likely to be less effective than Qsymia, more effective than Belviq.
2) Contrave (NB32) may be easier to obtain. Both Qsymia and Belviq are considered controlled substances, placing stiff limits on how doctors prescribe them. NB32 is not expected to be approved as a controlled substance, meaning doctors can hand out samples and meet less stringent criteria when prescribing.
3) Obesity treatment – and insurance coverage – is easier to get now.
4) Some people need the extra help of a drug.
5) Obesity drugs have side effects. But Contrave is Safer than other optios...
6) Contrave might lighten your mood as well.
CEO of Arena, Jack Lief, recently indicated this dynamic on a CNBC interview. What we see in the first few weeks of the Contrave launch, at least potentially, is that doctors seemed ready, willing, and indeed did write an impressive amount of scripts for Contrave.
OREX reported a 9 cent per share profit in Q3 of 2014 on $30 million in milestones related to the anti-obesity drug Contrave. The company conducted its Q3 2014 conference call this morning prior to the market opening.
Contrave launched in the beginning of October and has seen soft numbers during the initial two weeks of script numbers. Prior to launch it was widely anticipated that Contrave would utilize free samples to gain market penetration. Because Contrave is not a DEA scheduled drug, such a program would be easy to implement. Instead of taking that route, market partner Takeda set a very low price point that is as low as $45 per month for people with insurance, and $60 per month for those without.
Orexigen disclosed today that in the second week of launch over 5,000 scripts had been filed for filling at the mail order center that handles the "Direct Save" program. This number should be exciting to investors on the heels of very modest numbers reported by IMS Health for those first two weeks. It is still not known if the mail center scripts report its numbers to IMS Health, or if IMS Health will need to estimate sales through this center. If we add the IMS reported numbers to the 5,000 scripts that have been filed, the firsttwo weeks would total about 6,000 scripts, a launch that is on track for creating a decent move in the stock price.
The M&A activity among mid-market players to spread through the mining world over the rest of 2014 and into 2015. “I think we are going to see that move up the food chain
Mr. Ainley has the advantage of working on some of those proposed deals. “Our pipeline for M&A in mining now is quite filled in,” Mr. Ainley said. “There is a little more confidence in a couple of the commodity pricing situations.”
Jay Kellerman, managing partner with Stikeman Elliott LLP in Toronto, views stability in commodity pricing as a key ingredient to accelerating M&A activity. He points to the spirited takeover fight for Osisko Mining Corp. that was won by Yamana Gold Inc. and Agnico Eagle Gold Inc. over a rival bid from Goldcorp Inc.
Gold Buyback pressure is mounting high + AUY Analyst Upgrade